Regeneron at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Regeneron exhibits at Booth 1229 at ASH 2026 in New Orleans, and takes part in 1 session. Its presence centres on bispecific antibodies, as it supports symposia on launching them for multiple myeloma in community practice and using them earlier in non-Hodgkin lymphoma. It also supports a symposium on earlier diagnosis of AL amyloidosis and takes part in a scientific program on tissue-resident memory T cells.
| Organization | ASH 2026 Attendance |
|---|---|
Regeneron Tarrytown, NY | |
Biotechnology company developing antibody medicines, including bispecific antibodies for multiple myeloma and non-Hodgkin lymphoma. | Booth Exhibiting at Booth 1229 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together Diagnosing light-chain amyloidosis earlier, personalizing treatment including fibril-targeting drugs, supporting patients, and improving team workflows. Symposium Fri Dec 11 7:00am–10:00am Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice Bringing bispecific antibodies for multiple myeloma into community clinics, with patient selection, sequencing, toxicity management, and outpatient setup. Symposium Fri Dec 11 3:00pm–6:00pm The Rising Tide of Bispecifics in NHL: Off-the-Shelf Opportunities From Later-Line to Frontline Care Bispecific antibodies moving from late to early treatment of non-Hodgkin lymphoma, with outpatient step-up dosing and control of immune side effects. Session T Resident Memory Cells (Trm) in Health, Disease, and Therapeutics Memory T cells that stay put in tissues drive chronic inflammation after infection, in tumors, and after transplant, and the pathways keeping them alive. |
Instantly find 20 buyers from Regeneron
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction